Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NUDT15 | Q9NV35 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.42 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.42 |
| ▸ | GLRB | P48167 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1627652 | 0.99 | KMT2A (0.64) | KMT2AMEN1MAPTLMNATSHR | |
| SCHEMBL12719801 | 0.90 | KMT2A (0.55) | KMT2AMEN1MAPTLMNATSHR | |
| Hydrochloric Acid SCHEMBL1627336 | 0.89 | KMT2A (0.54) | KMT2AMEN1MAPTLMNATSHR | |
| SCHEMBL1626643 | 0.82 | LMNA (0.52) | KMT2AMEN1MAPTLMNATSHR | |
| SCHEMBL12719752 | 0.80 | SMN1; SMN2 (0.69) | KMT2AMEN1MAPTLMNATSHR | |
| SCHEMBL12719721 | 0.80 | SMN1; SMN2 (0.58) | KMT2AMEN1LMNATSHRCYP2C19 | |
| Hydrochloric Acid SCHEMBL1628271 | 0.79 | SMN1; SMN2 (0.57) | KMT2AMEN1LMNATSHRCYP2C19 | |
| SCHEMBL12719663 | 0.78 | ALDH1A1 (0.61) | KMT2AMEN1MAPTLMNATSHR | |
| Hydrochloric Acid SCHEMBL1625857 | 0.77 | ALDH1A1 (0.60) | KMT2AMEN1MAPTLMNATSHR | |
| SCHEMBL12719766 | 0.77 | MEN1 (0.48) | KMT2AMEN1MAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831195-B1 | 5-HT7 RECEPTOR ANTAGONISTS | ESTEVE LABOR DR (ES) | 2012-12-19 | — | — | EP | claimed |
| EP-1831195-B1 | 5-HT7 RECEPTOR ANTAGONISTS | ESTEVE LABOR DR (ES) | 2012-12-19 | — | — | EP | disclosed |
| US-7928121-B2 | 2-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolinehydrochloride; antidepressant, anxiolytic, hypotensive agent; psychosis, schizophrenia, migraine, cognition activity; pharmacokinetics | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-19 | — | — | US | disclosed |
| US-7928121-B2 | 2-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolinehydrochloride; antidepressant, anxiolytic, hypotensive agent; psychosis, schizophrenia, migraine, cognition activity; pharmacokinetics | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-19 | — | — | US | disclosed |
| US-7928121-B2 | 2-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolinehydrochloride; antidepressant, anxiolytic, hypotensive agent; psychosis, schizophrenia, migraine, cognition activity; pharmacokinetics | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-19 | — | — | US | disclosed |
| US-20080214603-A1 | 5-Ht7 Receptor Antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-09-04 | — | — | US | disclosed |
| US-20080214603-A1 | 5-Ht7 Receptor Antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-09-04 | — | — | US | disclosed |
| US-20080214603-A1 | 5-Ht7 Receptor Antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-09-04 | — | — | US | disclosed |
| US-7345057-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-18 | — | — | US | disclosed |
| US-7345057-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-18 | — | — | US | disclosed |
| US-7345057-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-18 | — | — | US | disclosed |
| US-20060142332-A1 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214603-A1 | 5-Ht7 Receptor Antagonists | HTR7, HTR1A, HTR5A | KMT2A 2422/4885MEN1 1107/4885MAPT 1463/4885 |
| US-20060142332-A1 | 5-HT7 receptor antagonists | HTR7, HTR1A, HTR5A | KMT2A 2373/4885MEN1 1322/4885MAPT 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.